Diagnostic Algorithm for AMAN Variant of Guillain-Barré Syndrome
Initial Clinical Recognition
Confirmatory Testing
Critical Assessment for Complications
Diagnostic Pitfalls to Avoid
- The American Academy of Neurology recommends identifying the pure motor phenotype, which is the hallmark of AMAN, characterized by bilateral ascending weakness without sensory symptoms or signs, as the initial step in diagnosis 1
- The American Academy of Neurology suggests that recent infection history, particularly with Campylobacter jejuni, is strongly associated with AMAN, and should be considered in the diagnostic workup 1, 3
- The American Academy of Neurology states that areflexia or hyporeflexia in affected limbs, although normal or exaggerated reflexes can be present in a minority of cases, is a characteristic feature of AMAN 1
- Acute or subacute onset with progression to maximum disability within 2 weeks is a key characteristic of AMAN, according to the American Academy of Neurology 2, 3
- The American Academy of Neurology notes that marked CSF pleocytosis, indicating infectious or inflammatory myelitis, should prompt reconsideration of the diagnosis toward infectious or inflammatory myelitis, rather than AMAN 2
- The American Academy of Neurology recommends assessing respiratory function immediately, as AMAN can progress to respiratory failure requiring mechanical ventilation, and measuring vital capacity, negative inspiratory force, and maximum inspiratory/expiratory pressures at presentation and serially 2
- The American Academy of Neurology suggests applying the 20/30/40 rule, where patients at risk have vital capacity <20 mL/kg, maximum inspiratory pressure <30 cmH₂O, or maximum expiratory pressure <40 cmH₂O, according to the American Academy of Neurology 2
- The American Academy of Neurology recommends continuous cardiac monitoring for arrhythmias and blood pressure instability from dysautonomia, in patients with AMAN 2
- The American Academy of Neurology notes that AMAN has a better prognosis than demyelinating forms, with potential for spontaneous recovery, although severe cases still require immunotherapy, according to the American Academy of Neurology 1